vs

Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and Udemy, Inc. (UDMY). Click either name above to swap in a different company.

Axsome Therapeutics, Inc. is the larger business by last-quarter revenue ($196.0M vs $194.0M, roughly 1.0× Udemy, Inc.). Udemy, Inc. runs the higher net margin — -1.2% vs -14.6%, a 13.4% gap on every dollar of revenue. On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs -3.0%). Udemy, Inc. produced more free cash flow last quarter ($15.0M vs $-18.7M). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs -0.7%).

Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.

Udemy is a US-based education technology company. Founded as a massive open online course (MOOC) provider in 2010 by Eren Bali, Gagan Biyani, and Oktay Caglar; the company is based in San Francisco, California, with offices in the United States, Australia, India, Ireland, Mexico and Turkey. Its education platform allows both the creation and sharing of online courses. By early 2025, Udemy claimed to have millions of individual users. Courses are typically video-based and on-demand.

AXSM vs UDMY — Head-to-Head

Bigger by revenue
AXSM
AXSM
1.0× larger
AXSM
$196.0M
$194.0M
UDMY
Growing faster (revenue YoY)
AXSM
AXSM
+68.0% gap
AXSM
65.0%
-3.0%
UDMY
Higher net margin
UDMY
UDMY
13.4% more per $
UDMY
-1.2%
-14.6%
AXSM
More free cash flow
UDMY
UDMY
$33.7M more FCF
UDMY
$15.0M
$-18.7M
AXSM
Faster 2-yr revenue CAGR
AXSM
AXSM
Annualised
AXSM
61.7%
-0.7%
UDMY

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
AXSM
AXSM
UDMY
UDMY
Revenue
$196.0M
$194.0M
Net Profit
$-28.6M
$-2.3M
Gross Margin
66.0%
Operating Margin
-13.8%
-1.8%
Net Margin
-14.6%
-1.2%
Revenue YoY
65.0%
-3.0%
Net Profit YoY
61.9%
76.4%
EPS (diluted)
$-0.55
$-0.01

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AXSM
AXSM
UDMY
UDMY
Q4 25
$196.0M
$194.0M
Q3 25
$171.0M
$195.7M
Q2 25
$150.0M
$199.9M
Q1 25
$121.5M
$200.3M
Q4 24
$118.8M
$199.9M
Q3 24
$104.8M
$195.4M
Q2 24
$87.2M
$194.4M
Q1 24
$75.0M
$196.8M
Net Profit
AXSM
AXSM
UDMY
UDMY
Q4 25
$-28.6M
$-2.3M
Q3 25
$-47.2M
$1.6M
Q2 25
$-48.0M
$6.3M
Q1 25
$-59.4M
$-1.8M
Q4 24
$-74.9M
$-9.9M
Q3 24
$-64.6M
$-25.3M
Q2 24
$-79.3M
$-31.8M
Q1 24
$-68.4M
$-18.3M
Gross Margin
AXSM
AXSM
UDMY
UDMY
Q4 25
66.0%
Q3 25
65.9%
Q2 25
66.1%
Q1 25
64.6%
Q4 24
63.6%
Q3 24
63.0%
Q2 24
62.3%
Q1 24
61.2%
Operating Margin
AXSM
AXSM
UDMY
UDMY
Q4 25
-13.8%
-1.8%
Q3 25
-27.0%
-0.1%
Q2 25
-24.5%
2.0%
Q1 25
-46.9%
-2.2%
Q4 24
-61.1%
-5.8%
Q3 24
-59.8%
-15.1%
Q2 24
-89.5%
-13.1%
Q1 24
-89.7%
-11.5%
Net Margin
AXSM
AXSM
UDMY
UDMY
Q4 25
-14.6%
-1.2%
Q3 25
-27.6%
0.8%
Q2 25
-32.0%
3.1%
Q1 25
-48.9%
-0.9%
Q4 24
-63.1%
-4.9%
Q3 24
-61.7%
-12.9%
Q2 24
-91.0%
-16.4%
Q1 24
-91.1%
-9.3%
EPS (diluted)
AXSM
AXSM
UDMY
UDMY
Q4 25
$-0.55
$-0.01
Q3 25
$-0.94
$0.01
Q2 25
$-0.97
$0.04
Q1 25
$-1.22
$-0.01
Q4 24
$-1.54
$-0.06
Q3 24
$-1.34
$-0.17
Q2 24
$-1.67
$-0.21
Q1 24
$-1.44
$-0.12

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AXSM
AXSM
UDMY
UDMY
Cash + ST InvestmentsLiquidity on hand
$322.9M
$358.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$88.3M
$210.5M
Total Assets
$689.8M
$617.7M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AXSM
AXSM
UDMY
UDMY
Q4 25
$322.9M
$358.7M
Q3 25
$325.3M
$371.2M
Q2 25
$303.0M
$392.0M
Q1 25
$300.9M
$357.0M
Q4 24
$315.4M
$354.4M
Q3 24
$327.3M
$357.1M
Q2 24
$315.7M
$420.9M
Q1 24
$331.4M
$430.7M
Stockholders' Equity
AXSM
AXSM
UDMY
UDMY
Q4 25
$88.3M
$210.5M
Q3 25
$73.7M
$221.8M
Q2 25
$73.1M
$233.4M
Q1 25
$53.2M
$209.4M
Q4 24
$57.0M
$197.4M
Q3 24
$92.9M
$196.3M
Q2 24
$102.9M
$252.3M
Q1 24
$144.0M
$296.5M
Total Assets
AXSM
AXSM
UDMY
UDMY
Q4 25
$689.8M
$617.7M
Q3 25
$669.3M
$618.9M
Q2 25
$639.8M
$644.0M
Q1 25
$596.7M
$639.0M
Q4 24
$568.5M
$605.6M
Q3 24
$561.5M
$608.9M
Q2 24
$548.2M
$671.9M
Q1 24
$545.7M
$708.5M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AXSM
AXSM
UDMY
UDMY
Operating Cash FlowLast quarter
$-18.7M
$15.5M
Free Cash FlowOCF − Capex
$-18.7M
$15.0M
FCF MarginFCF / Revenue
-9.6%
7.7%
Capex IntensityCapex / Revenue
0.0%
0.3%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-93.9M
$81.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AXSM
AXSM
UDMY
UDMY
Q4 25
$-18.7M
$15.5M
Q3 25
$1.0M
$15.7M
Q2 25
$-32.4M
$44.2M
Q1 25
$-43.4M
$12.2M
Q4 24
$-26.2M
$9.6M
Q3 24
$-18.6M
$-6.1M
Q2 24
$-30.1M
$28.6M
Q1 24
$-53.5M
$21.0M
Free Cash Flow
AXSM
AXSM
UDMY
UDMY
Q4 25
$-18.7M
$15.0M
Q3 25
$988.0K
$15.1M
Q2 25
$-32.4M
$41.9M
Q1 25
$-43.7M
$9.8M
Q4 24
$-26.2M
$8.4M
Q3 24
$-18.7M
$-6.7M
Q2 24
$-30.2M
$28.2M
Q1 24
$-53.6M
$20.8M
FCF Margin
AXSM
AXSM
UDMY
UDMY
Q4 25
-9.6%
7.7%
Q3 25
0.6%
7.7%
Q2 25
-21.6%
21.0%
Q1 25
-36.0%
4.9%
Q4 24
-22.1%
4.2%
Q3 24
-17.9%
-3.4%
Q2 24
-34.6%
14.5%
Q1 24
-71.4%
10.6%
Capex Intensity
AXSM
AXSM
UDMY
UDMY
Q4 25
0.0%
0.3%
Q3 25
0.0%
0.3%
Q2 25
0.0%
1.1%
Q1 25
0.3%
1.2%
Q4 24
0.0%
0.6%
Q3 24
0.1%
0.3%
Q2 24
0.1%
0.2%
Q1 24
0.1%
0.1%
Cash Conversion
AXSM
AXSM
UDMY
UDMY
Q4 25
Q3 25
9.58×
Q2 25
7.06×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons